These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 38044486)

  • 1. Evaluation of the potential impact on pharmacokinetics of various cytochrome P450 substrates of increasing IL-6 levels following administration of the T-cell bispecific engager glofitamab.
    Djebli N; Parrott N; Jaminion F; O'Jeanson A; Guerini E; Carlile D
    CPT Pharmacometrics Syst Pharmacol; 2024 Mar; 13(3):396-409. PubMed ID: 38044486
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of Drug-Drug Interaction Potential of Talquetamab, a T-Cell-Redirecting GPRC5D × CD3 Bispecific Antibody, as a Result of Cytokine Release Syndrome in Patients with Relapsed/Refractory Multiple Myeloma in MonumenTAL-1, Using a Physiologically Based Pharmacokinetic Model.
    Willemin ME; Gong J; Hilder BW; Masterson T; Tolbert J; Renaud T; Heuck C; Kane C; De Zwart L; Girgis S; Ma X; Ouellet D
    Target Oncol; 2024 Nov; 19(6):965-979. PubMed ID: 39285155
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Drug-drug interaction (DDI) assessments of ruxolitinib, a dual substrate of CYP3A4 and CYP2C9, using a verified physiologically based pharmacokinetic (PBPK) model to support regulatory submissions.
    Umehara K; Huth F; Jin Y; Schiller H; Aslanis V; Heimbach T; He H
    Drug Metab Pers Ther; 2019 May; 34(2):. PubMed ID: 31145690
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development of a Physiologically Based Pharmacokinetic Model to Predict Disease-Mediated Therapeutic Protein-Drug Interactions: Modulation of Multiple Cytochrome P450 Enzymes by Interleukin-6.
    Jiang X; Zhuang Y; Xu Z; Wang W; Zhou H
    AAPS J; 2016 May; 18(3):767-76. PubMed ID: 26961818
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro inhibition of human cytochrome P450 enzymes by the novel atypical antipsychotic drug asenapine: a prediction of possible drug-drug interactions.
    Wójcikowski J; Danek PJ; Basińska-Ziobroń A; Pukło R; Daniel WA
    Pharmacol Rep; 2020 Jun; 72(3):612-621. PubMed ID: 32219694
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Therapeutic Protein Drug Interaction Potential in Subjects With Psoriasis: An Assessment Based on Population Pharmacokinetic Analyses of Sensitive Cytochrome P450 Probe Substrates.
    Sathe AG; Othman AA; Mohamed MF
    J Clin Pharmacol; 2021 Mar; 61(3):307-318. PubMed ID: 32960975
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Physiologically Based Pharmacokinetic Model to Assess the Influence of Blinatumomab-Mediated Cytokine Elevations on Cytochrome P450 Enzyme Activity.
    Xu Y; Hijazi Y; Wolf A; Wu B; Sun YN; Zhu M
    CPT Pharmacometrics Syst Pharmacol; 2015 Sep; 4(9):507-15. PubMed ID: 26451330
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Abemaciclib Does Not Have a Clinically Meaningful Effect on Pharmacokinetics of CYP1A2, CYP2C9, CYP2D6, and CYP3A4 Substrates in Patients with Cancer.
    Turner PK; Hall SD; Chapman SC; Rehmel JL; Royalty JE; Guo Y; Kulanthaivel P
    Drug Metab Dispos; 2020 Sep; 48(9):796-803. PubMed ID: 32581049
    [TBL] [Abstract][Full Text] [Related]  

  • 9.
    Zhang N; Liu J; Chen Z; Dou W
    Pharm Biol; 2019 Dec; 57(1):571-576. PubMed ID: 31456483
    [No Abstract]   [Full Text] [Related]  

  • 10. Glofitamab, a Novel, Bivalent CD20-Targeting T-Cell-Engaging Bispecific Antibody, Induces Durable Complete Remissions in Relapsed or Refractory B-Cell Lymphoma: A Phase I Trial.
    Hutchings M; Morschhauser F; Iacoboni G; Carlo-Stella C; Offner FC; Sureda A; Salles G; Martínez-Lopez J; Crump M; Thomas DN; Morcos PN; Ferlini C; Bröske AE; Belousov A; Bacac M; Dimier N; Carlile DJ; Lundberg L; Perez-Callejo D; Umaña P; Moore T; Weisser M; Dickinson MJ
    J Clin Oncol; 2021 Jun; 39(18):1959-1970. PubMed ID: 33739857
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Physiologically based pharmacokinetic modeling to assess metabolic drug-drug interaction risks and inform the drug label for fedratinib.
    Wu F; Krishna G; Surapaneni S
    Cancer Chemother Pharmacol; 2020 Oct; 86(4):461-473. PubMed ID: 32886148
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Investigation of sarizotan's impact on the pharmacokinetics of probe drugs for major cytochrome P450 isoenzymes: a combined cocktail trial.
    Krösser S; Neugebauer R; Dolgos H; Fluck M; Rost KL; Kovar A
    Eur J Clin Pharmacol; 2006 Apr; 62(4):277-84. PubMed ID: 16525816
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Simulating the Impact of Elevated Levels of Interleukin-6 on the Pharmacokinetics of Various CYP450 Substrates in Patients with Neuromyelitis Optica or Neuromyelitis Optica Spectrum Disorders in Different Ethnic Populations.
    Machavaram KK; Endo-Tsukude C; Terao K; Gill KL; Hatley OJ; Gardner I; Parrott N; Ducray PS
    AAPS J; 2019 Mar; 21(3):42. PubMed ID: 30887238
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Blinatumomab, a Bispecific T-cell Engager (BiTE(®)) for CD-19 Targeted Cancer Immunotherapy: Clinical Pharmacology and Its Implications.
    Zhu M; Wu B; Brandl C; Johnson J; Wolf A; Chow A; Doshi S
    Clin Pharmacokinet; 2016 Oct; 55(10):1271-1288. PubMed ID: 27209293
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Assessment of interaction potential of AZD2066 using in vitro metabolism tools, physiologically based pharmacokinetic modelling and in vivo cocktail data.
    Nordmark A; Andersson A; Baranczewski P; Wanag E; Ståhle L
    Eur J Clin Pharmacol; 2014 Feb; 70(2):167-78. PubMed ID: 24186263
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro and in vivo assessment of the effect of dalcetrapib on a panel of CYP substrates.
    Derks M; Fowler S; Kuhlmann O
    Curr Med Res Opin; 2009 Apr; 25(4):891-902. PubMed ID: 19245299
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predictive Performance of Physiologically Based Pharmacokinetic (PBPK) Modeling of Drugs Extensively Metabolized by Major Cytochrome P450s in Children.
    Zhou W; Johnson TN; Bui KH; Cheung SYA; Li J; Xu H; Al-Huniti N; Zhou D
    Clin Pharmacol Ther; 2018 Jul; 104(1):188-200. PubMed ID: 29027194
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prediction of the drug-drug interaction potential of the α1-acid glycoprotein bound, CYP3A4/CYP2C9 metabolized oncology drug, erdafitinib.
    De Zwart L; Snoeys J; Jacobs F; Li LY; Poggesi I; Verboven P; Goris I; Scheers E; Wynant I; Monshouwer M; Mamidi RNVS
    CPT Pharmacometrics Syst Pharmacol; 2021 Sep; 10(9):1107-1118. PubMed ID: 34273250
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Assessment of CYP3A-mediated drug interaction via cytokine (IL-6) elevation for mosunetuzumab using physiologically-based pharmacokinetic modeling.
    Chen Y; Ma F; Jones N; Deng R; Li C; Li CC
    CPT Pharmacometrics Syst Pharmacol; 2024 Feb; 13(2):234-246. PubMed ID: 38050329
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prediction of maternal pharmacokinetics using physiologically based pharmacokinetic models: assessing the impact of the longitudinal changes in the activity of CYP1A2, CYP2D6 and CYP3A4 enzymes during pregnancy.
    Abduljalil K; Pansari A; Jamei M
    J Pharmacokinet Pharmacodyn; 2020 Aug; 47(4):361-383. PubMed ID: 32840724
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.